68 related articles for article (PubMed ID: 16796007)
1. Influence of HMG-CoA-reductase inhibitors on the body fat status.
Bucek RA; Reiter M; Wirth S; Pourazim A; Minar E
Vasa; 2006 May; 35(2):92-5. PubMed ID: 16796007
[TBL] [Abstract][Full Text] [Related]
2. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
5. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
7. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin.
Raal FJ
Cardiovasc J S Afr; 2004; 15(3):118-23. PubMed ID: 15258621
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Su Y; Xu Y; Sun YM; Li J; Liu XM; Li YB; Liu GD; Bi S
J Cardiovasc Pharmacol; 2010 Jan; 55(1):21-5. PubMed ID: 19786892
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Jacobson TA; Wertz DA; Hoy T; Kuznik A; Grochulski D; Cziraky M
Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
[TBL] [Abstract][Full Text] [Related]
10. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Thelen KM; Laaksonen R; Päivä H; Lehtimäki T; Lütjohann D
J Clin Pharmacol; 2006 Jul; 46(7):812-6. PubMed ID: 16809807
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Neuhaus O; Hartung HP
Expert Rev Neurother; 2007 May; 7(5):547-56. PubMed ID: 17492904
[TBL] [Abstract][Full Text] [Related]
14. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
15. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
[TBL] [Abstract][Full Text] [Related]
16. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
17. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
18. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
19. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
20. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
